GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » 3-Year Share Buyback Ratio

GBIO (Generation Bio Co) 3-Year Share Buyback Ratio : -5.50% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Generation Bio Co 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Generation Bio Co's current 3-Year Share Buyback Ratio was -5.50%.

The historical rank and industry rank for Generation Bio Co's 3-Year Share Buyback Ratio or its related term are showing as below:

GBIO' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -12.8   Med: -11.9   Max: -5.5
Current: -5.5

During the past 7 years, Generation Bio Co's highest 3-Year Share Buyback Ratio was -5.50%. The lowest was -12.80%. And the median was -11.90%.

GBIO's 3-Year Share Buyback Ratio is ranked better than
64.03% of 1251 companies
in the Biotechnology industry
Industry Median: -9.8 vs GBIO: -5.50

Competitive Comparison of Generation Bio Co's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Generation Bio Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generation Bio Co's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generation Bio Co's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Generation Bio Co's 3-Year Share Buyback Ratio falls into.


;
;

Generation Bio Co 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Generation Bio Co (NAS:GBIO) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Generation Bio Co 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Generation Bio Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » 3-Year Share Buyback Ratio
Comparable Companies
BCAB ALXO NNVC OVID CRIS BOLD ELEV NRXS VYNE FGEN VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.generationbio.com
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Executives
Anthony G. Quinn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Antoinette Paone officer: CHIEF OPERATING OFFICER C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Dannielle Appelhans director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson director C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Yalonda Howze officer: CHIEF LEGAL OFFICER C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa officer: CHIEF STRATEGY OFFICER C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton officer: Chief Scientific Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr officer: Chief Development Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough director, 10 percent owner, officer: See Remarks C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann officer: Chief Development Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino officer: Chief Operating Officer GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142